Archive | Next Phase Archive RSS feed for this section

Boston Innovation Capital Celebrates Our One Year Anniversary

27 Apr

By Colin Widen, CEO, Boston Innovation Capital

Boston Innovation Capital (BIC), a wholly owned subsidiary of LSN Holdings, became a FINRA-registered broker dealer in 2016. BIC works alongside LSN’s other two divisions (LSN’s Investor Platform and Company Platform, and the RESI Conference Group) to support early stage companies in forging connections with investors, major pharma firms and other strategic players in the life science world.

With a year of operations under our belt, BIC has expanded its services to support both startups and investors in building early stage connections based on a good fit between buyers and sellers of new life science innovations.

BIC was founded to create and execute global fundraising campaigns for startups in the biotech, medical devices, diagnostics and healthcare IT sectors. This was a logical start for the firm due to BIC’s relationship with Life Science Nation. The conversation that LSN maintains with the industry via the RESI events and the LSN Investor Platform creates a close relationship with investors and deep awareness of the fundraising landscape.

These relationships have also given BIC the capacity to offer buy side services. BIC can often make confidential inquiries to investors regarding their portfolio companies. This gives BIC access to tens of thousands of private companies that are extremely difficult to source. Not only does BIC get access via these investors but they receive a potential introduction by in many cases an investor who has a board seat. This puts BIC in a unique position to represent entities looking to license or acquire assets.

LSN’s unique position in the early stage space, and the range of capabilities we have developed, provide a strong foundation for a sourcing and ranking service for clients interested in investment/acquisition opportunities. LSN is uniquely positioned to rapidly identify and assess technology assets for clients focusing on any disease area of interest. We operate at the intersection of many North American and European channels of early stage life science technology assets.

LSN has deep relationships with Big Pharma players, large global CRO’s and other service providers who are all long-term clients. LSN owns and curates one of the top early stage company databases in the world and sells this database to these partners who use it to source early stage life science technology. This global positioning, along with the appearance of exciting new companies/technologies at our RESI meetings and deep relationships with our partners (pharma, NIH, investors) enables LSN to provide our clients with a comprehensive view of their interest areas.

The Sourcing and Ranking Service (SRS) provides clients with a comprehensive opportunity to make the sourcing process super efficient. Starting with a detailed assessment of the clients’ investment interests, LSN will conduct a global search for assets in that interest area; will vet and rank the most relevant assets; will provide the client with a deep dive analysis of the companies holding the top 10 to 20 assets. SRS is designed to provide clients with a rapid, end-to-end business development research capability that will enable them to more quickly access the assets they are most interested in.

If you’re interested in how to source, vet and rank new assets, stay tuned, because we’ll cover this in depth in next week’s newsletter. We look forward to building on our resources and relationships in the years to come, and offering both startups and investors more support in finding the right match.

Branding Your Life Science Startup – The Logo and Tagline Are More Important Than You Might Think

27 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Having a clear and consistent identity and message—or brand—that differentiates you is a critical requirement in establishing yourself as an investible identity to your prospective capital providers.

Many life science executives falsely believe that only consumer goods companies must invest in branding. Many also believe that their technology is so compelling that it will speak for itself. The reality is that branding is equally important in the life sciences, especially when it comes to raising capital, and that selling even the best of products takes some work.

Although you’re communicating with a small and highly educated audience, branding influences the choices they make. Your brand is what you present to the world. In creating it, you must ask yourself how you want to present your company and product and how you want to be seen and perceived. A logo may seem like a trivial component, but it’s actually an opportunity for you to create an image in an investor’s mind.

The goal of logo development is to create one that embodies the identity of your firm. Your logo is a symbolic representation of what your firm is all about, and it (like your marketing collateral) needs to be clear, crisp, and obvious. Too often, entrepreneurs will pick a logo that is inscrutable to an investor (for example, a complex molecular diagram) without thinking about it from a marketing perspective. You must take the time to consider what differentiates your company from the rest of the marketplace, what values your company holds, and what message you are trying to send. If you take the time to think through these questions, you’ll be able to develop a logo that is a strong and simple representation of the image you are striving to achieve in the marketplace.

Right below your logo should be your tagline. A tagline communicates in one crisp statement who you are and what you do. A common mistake people make is writing taglines that are general and nondescriptive rather than crisp and compelling. Examples of poor ones are “Moving Science Forward,” “Next Generation Solutions,” and “Creating New Therapies.” These don’t say anything specific about what the company does. A great tagline explains precisely what you do in a few words and starts to provide the context for who the company is.

Some examples of successful taglines include “Inventors of a Novel, Safe Anti-Cancer Agent” and “Anti-Infective Preventing the Replication of the Hep B Virus.” Life Science Nation’s tagline is “Connecting Products, Services & Capital.” The tagline needs to capture the essence of what your company does so that the reader has a general idea of what you are about. In the case of the latter example, the company name “Life Science Nation defines the arena the company plays in. The tagline informs the reader of the company’s role within that space.

Are your logo and tagline up to the task of representing your brand? LSN is launching a contest to find the best startup branding in the life sciences. Send in your logo and tell us the 5-7 word tagline for your startup, and we’ll feature the best submissions in a future edition of this newsletter, which will go out to 40,000 readers around the world.

Key Stakeholders Share the Value of RESI for Early Stage Investors and Startups

27 Apr

By Natasha Eldridge, RESI Conference Manager, LSN


In San Diego on June 19th, the Redefining Early Stage Investments (RESI) Conference will bring a new, early stage focused discussion venue for startups and investors who are visiting BIO week and want more opportunities to connect. What makes RESI different? At our last event, RESI on MaRS in Toronto, we asked our key stakeholders this question and here’s what they told us.

Ying Tam – Head of Digital Health – MaRS Discovery District

“All the research says that one of the critical elements for an entrepreneur ecosystem, especially in health, is funding and investment. It takes a long time to nurture a health company, to get it to market and commercialization and scale. So, investment is critical for the development of a startup in health. RESI brings in a whole set of investors from across North America and across the world.”

Rebecca Yu – Head of JLABS @ TorontoJohnson & Johnson Innovation JLABS

“RESI attracts many repeat attendees, and that speaks to me that there’s a story, there’s something here. There’s great stuff happening here for entrepreneurs. There’s early stage companies from across Canada, from pharmaceuticals to medical devices to consumer health, and of course there’s a big digital health and AI presence here in Toronto. That’s why JLABS and J&J are here. We play in all the sectors, we partner with different groups within this ecosystem, and we see LSN/RESI as a key partner as well, to bring investors to this ecosystem.”

Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec

“The RESI conference is an opportunity to help out these early stage companies such that they can achieve inflection points. If I can identify companies early, then I might become a vendor of choice for them. Getting in early becomes an important objective for me. When I come to a conference like RESI, I come to these early stage companies who are really looking for partnering with investors here, but also get an opportunity to introduce WuXi to them as well.”

RESI attendees can book up to 16 meetings with investors in one day, right at the start of BIO Week. If you want to take this opportunity to start your BIO with a bang, register now.

RESI San Diego – Early Bird Rate Ends Tomorrow

20 Apr

By Lucy Parkinson, Director of Research, LSN

For the first time, the Redefining Early Stage Investments (RESI) Conference is coming to San Diego, CA. On Monday June 19th, of Bio week, RESI will provide an opportunity to start your week at the Westin San Diego Gaslamp Quarter with up to 16 face to face meetings with the most relevant global investors for your technology. Not only that, but 3 full-day program tracks of investor panels and workshops will help scientist-entrepreneurs learn the ins and outs of early stage fundraising issues.

RESI’s early bird rate ends tomorrow.  If you are headed to BIO and want to achieve maximum ROI on your trip to San Diego, get your RESI pass today.


RESI San Diego Agenda Announcement

20 Apr

By Michael Quigley, VP of Market Research, LSN


For its first trip to San Diego, the Redefining Early Stage Investments (RESI) conference team will be bringing with it a content rich agenda. RESI’s Biotech and Medtech tracks will feature over 75 investor speakers across 16 panels devoted to specific investor types, technology sectors, or new issues in fundraising. Representatives from family offices, big pharma, VC, angels and more will share with the audience the types of opportunities they are currently looking for as well as what it is like to be on the other side of the negotiating table.

RESI’s Early Stage Workshops track features 4 entrepreneur education workshops, including a new session on 505(b)(2) Strategy led by Ken Phelps, CEO of Camargo.

With our Asia-North America Track, one of our newer and most popular additions, attendees will get the chance to hear directly from investors and strategic partners from across the Pacific looking for North American innovation. These panels will be a must-see for any fundraising entrepreneur in the sector.

We are very excited to bring this diverse pool of investors and speakers to San Diego to share their expertise and experience with the hundreds of fundraising scientist-entrepreneurs who attend RESI. While many of our speaking spots are already allocated, if you or someone you know would want to participate please don’t hesitate to reach out.

Get Your Startup in the Spotlight at the RESI Innovation Challenge in San Diego

20 Apr

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

RESI is going to BIO. As we join 2017’s largest life science innovation carnival, we aim to showcase the most promising, innovative new health technologies in the RESI Innovation Challenge. If you’re headed to San Diego with the aim of raising money or making deals for your startup, we’d like to see your application.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On June 19th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder, Steadiwear | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

RESI on MaRS 2017 Innovation Challenge 1st Place Winner – Steadiwear inc.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.


Here is what our previous winners are saying about the RESI Innovation Challenge:


“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”

– Raymond Shih, President, Co-Founder, QoC Health

3rd Place, RESI on MaRS, June 23, 2016


“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

Redefining Early Stage Investments (RESI) Conference on MaRS Report

13 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI’s first MaRS landing was in Summer 2016, and the success of the event revealed a tremendous appetite for an early stage life science investment venue in Toronto.

For 2017, RESI on MaRS built on its initial success to become the centerpiece of the new Toronto Health Innovation Week – a sequence of summits, conferences and receptions that gathered together the most vital players in Toronto’s healthcare ecosystem.  As RESI continues its cycle of events throughout North America, we look forward to working with local bio-med innovation hubs in every RESI city to showcase their innovations and technology resources.

Last week’s RESI on MaRS grew significantly over our 2016 event. Delegates came to RESI from 12 countries. There was a 25% increase in investor attendance. In all, more than 600 attendees came to RESI on MaRS to pitch their ideas or to find new investment opportunities.

More bandwidth was added for RESI Partnering meetings – RESI attendees exchanged over 3000 meeting requests, and 1000 scheduled one-on-one meetings took place. Outside of RESI Partnering, the halls of MaRS Discovery District buzzed with ad-hoc meetings and networking encounters.

30 companies competed in the RESI Innovation Challenge. The victor, Steadiwear, was a MaRS portfolio company.

Partnering Forum

RESI on MaRS also featured three full tracks of content. In RESI’s 16 investor panels, attendees heard from a wide variety of early stage investors and strategic players who are looking to Toronto for new technology opportunities. Some panels focused on a particular funding source such as Family Offices, Public Private Partnerships and Corporate Venture Capital. Others looked at the diversity of the investment landscape in a specific technology vertical, such as Diagnostics or Medical Devices. Meanwhile, the Tales From The Road panel – seasoned life science CEOs who have recent experience of raising capital – spoke about how they’d met the challenge of attracting global investors to back their Canadian startups.

Incubator Accelerator New Models Panel (Ying Tam, Managing Director Health, MaRS Discovery District | Frédéric Lemaitre Auger, Senior Director, Investments, Accel-Rx – Canada’s Health Science Accelerator | Rebecca Yu, Head of JLABS @ Toronto, Johnson & Johnson Innovation | Randy Yatscoff, Executive Vice President, Business Development, TEC Edmonton | Kristi Ebong, Head Strategy Business Development, Cedars-Sinai Health System)

The RESI Asia-North America Partnering Track was added to the event, drawing high level decision makers from healthcare investment firms and major healthcare corporations from China, Japan, Korea, and Taiwan. These investors defined their interest in investing in healthcare startups in Canada and the US, and explained how to work with a partner in Asia to reach a new marketplace and grow your company.

Asia Pharma Partners Panel (Hiroshi Kawai, Vice President, Mitsubishi Tanabe Holdings America | Tianle Redanz, Director of Business Development, Simcere of America | Weiyong Sun, Senior Director External Scientific Affairs, Daiichi Sankyo | Richard Soll, Senior Vice President, Research Service Division (RSD), WuXi AppTec)

It’s clear that Toronto has a strong ecosystem for generating new healthcare technologies and launching new companies, and RESI on MaRS has served as a catalyst to join those new technologies with relevant, active investors who see the advantages of investing in Canada. By building these new bridges between technology and capital, RESI on MaRS will move science forward in Toronto.

RESI’s next stop will be in San Diego on Monday June 19th – the first RESI event to take place concurrent with the BIO International Convention. If you’d like to join LSN for a day of investor meetings, new panel content and high level networking, you can register now.